Retatrutide 10MG

Sources & References

Peer-reviewed studies and references related to Retatrutide 10MG.

Nature Medicine

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial

2024 · Arun J Sanyal, Lee M Kaplan, Juan P Frias, Bram Brouwers, Qiwei Wu, Melissa K Thomas, Charles Harris, Nanette C Schloot, Yu Du, Kieren J Mather, Axel Haupt, Mark L Hartman

View Source ↗

The Lancet Diabetes & Endocrinology

Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial

2025 · Tamer Coskun, Qiwei Wu, Nanette C Schloot, Axel Haupt, Zvonko Milicevic, Courtney Khouli, Charles Harris

View Source ↗

Current Cardiovascular Risk Reports

Triple Agonism Based Therapies for Obesity

2025 · Jonathan Goldney, Malak Hamza, Farhaana Surti, Melanie J Davies, Dimitris Papamargaritis

View Source ↗

Proceedings (Baylor University Medical Center)

Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials

2025 · Alaa Abdrabou Abouelmagd, Amro Mamdouh Abdelrehim, Mohamed Nabih Bashir, Fares Abdelsalam, Ahmed Marey, Yousef Tanas, Duha Milad Abuklish, Mohamed Mohamed Belal

View Source ↗

Cell Discovery

Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide

2024 · Wenzhuo Li, Qingtong Zhou, Zhaotong Cong, Qingning Yuan, Wenxin Li, Fenghui Zhao, H. Eric Xu, Li-Hua Zhao, Dehua Yang, Ming-Wei Wang

View Source ↗

PubChem

Retatrutide - Compound Summary

View Source ↗